Author: admin

How Rob Harrison Is Sculpting Playa del Carmen Into Mexico’s Fitness Capital, One Workout at a Time

It started with a sunrise, a few bodyweight exercises, and a desire to connect. Today, what Rob Harrison has built in Playa del Carmen is more than just a workout group, it’s a movement. Through his vision, energy, and entrepreneurial spirit, PDC Fitness Club is transforming the city’s identity and putting Playa on the map as Mexico’s next big fitness destination.

From High-Ticket Sales to High-Intensity Training

Rob’s background isn’t what you’d expect from the leader of one of the most exciting fitness communities in Mexico. With 12 years military service, multiple business ventures and high-level sales coaching, Rob built a name for himself as a no-nonsense, results-driven entrepreneur. His specialty? Helping remote sales teams close high-ticket deals and scale fast.

But behind the numbers and the business success was a man deeply passionate about discipline, wellness, and connection.

When Rob relocated to Playa del Carmen in 2019, he saw an opportunity: not just to build online businesses, but to create something on the ground a community that embodied everything he believed in. That community became PDC Fitness Club.

Community-First Fitness, with a Brand-Builder’s Touch

Unlike many pop-up fitness sessions along the beach, Rob approached PDC Fitness Club like an entrepreneur would approach a start-up. There was a vision, a name, a logo, a vibe and most importantly, a culture.

Every morning, locals, digital nomads, and travellers meet at dawn for high-energy HIIT sessions, group runs, and social bonding. What keeps them coming back isn’t just the workouts, it’s the accountability, the positivity, and the tribe vibe Rob has carefully cultivated.

What’s especially unique is Rob’s approach. He applies his business background to build this community like a brand:

– Consistent programming that people can rely on

– Clear visual identity and branding

– Organic social media growth through community tagging and storytelling

– A focus on leadership, not just fitness, helping people become more disciplined, focused, and connected

Why Playa del Carmen? Why Now?

Playa del Carmen has always been known for its beaches and nightlife, but now, it’s rapidly gaining a reputation as a wellness and fitness hotspot. Rob saw the shift early.

“There were a lot of people here looking for structure, not just a place to party or lay on the beach,” he said in a recent chat. “They wanted connection, accountability, and something to belong to. That’s what we built.”

And it’s working. Each week, the group grows. People return. Friends are made. Workouts turn into business collaborations. The ripple effect is real.

A New Vision for Playa: The Fitness Capital of Mexico

What Rob is doing with PDC Fitness Club goes beyond squats and burpees. He’s part of a broader movement to redefine Playa del Carmen as a global fitness destination, a place where people come not just to relax, but to level up.

With new plans on the horizon including apparel drops, community events, and expanded class offerings. Rob is carving out a vision for Playa that blends entrepreneurship, lifestyle, and purpose.

From fitness tourists to expats and locals seeking balance, Rob’s influence is pulling people into a healthier rhythm and creating a culture that’s inspiring other coaches and communities to do the same.

About Rob Harrison

Rob is a former British military serviceman, high-ticket sales coach, and founder of PDC Fitness Club in Playa del Carmen. Known for his direct style, relentless discipline, and magnetic leadership, Rob blends his business acumen with a passion for fitness and mindset to build impactful communities around the world, both online and off.

Media Contact
Company Name: Magnifyde PR
Contact Person: Rob Harrison
Email: Send Email
Country: United States
Website: https://magnifydepr.com

David Alemian Launches Copyrighted Alemian Retention System to End First Responder Shortages in Police, Fire, and EMS with Confidential, Scalable, Zero Net Cost Solution

David Alemian Launches Copyrighted Alemian Retention System to End First Responder Shortages in Police, Fire, and EMS with Confidential, Scalable, Zero Net Cost Solution

“Our confidential, zero net cost retention strategy stops the exodus of police, firefighters, and EMS by aligning long-term financial security with loyalty,” said David Alemian.
David Alemian, America’s foremost talent retention expert, has launched the Alemian Retention System to help police, fire, and EMS agencies solve first responder shortages. This confidential, copyrighted system provides a zero net cost solution to stop preventable turnover, improve morale, and align public safety professionals with long-term staffing goals.

(Pictured) David Alemian, create of the Alemian Retention System
David Alemian Launches Confidential, Copyrighted Alemian Retention System to Solve National First Responder Staffing Crisis with Scalable, Zero Net Cost Strategy

San Diego, CA – Aug 11, 2025 – In response to the growing national emergency surrounding the chronic shortage of police officers, firefighters, and EMTs, acclaimed talent retention expert David Alemian has introduced a groundbreaking innovation designed specifically to stop the alarming levels of turnover in public safety agencies. The Alemian Retention System is a proprietary, confidential, and copyright-registered workforce retention strategy that offers a scalable, zero net cost solution for police departments, fire departments, and EMS agencies struggling to retain their most valuable personnel.

As communities across the United States face record-high vacancy rates in their first responder ranks, the consequences are growing more severe. Public safety response times are increasing, morale is falling, and overburdened emergency professionals are retiring early or transferring to the private sector. David Alemian, the nation’s leading authority on public safety retention, says these losses are entirely preventable. His Alemian Retention System addresses this crisis by providing long-term financial security to first responders in exchange for their continued commitment, effectively aligning their personal future with their department’s long-term stability.

“The Alemian Retention System is engineered to stop preventable turnover in police, fire, and EMS agencies by offering a confidential, cost-neutral incentive that rewards service and builds deep loyalty,” said David Alemian, creator of the program. “This is a solution built not only to fix staffing shortages, but to protect community safety and restore public trust,” added David Alemian.

Unlike traditional retention programs that rely on expensive short-term bonuses or benefits with unpredictable outcomes, the Alemian Retention System leverages a confidential and highly innovative structure that ensures the employer always recovers its investment, making the solution budget-neutral, cost-effective, and sustainable. The details of the financial strategy remain confidential to protect the integrity of the system, but Alemian confirms that it has received a Certificate of Registration from the U.S. Copyright Office, solidifying its status as a unique intellectual property unlike anything currently available to public safety departments.

This exclusive retention framework is designed to prevent early retirements, eliminate turnover costs, restore depleted ranks, reduce burnout, increase employee morale, and ultimately help departments retain their best people while rebuilding trust in public service. The system is especially attractive to municipal leaders, police chiefs, fire chiefs, and EMS directors seeking a strategic solution to long-term workforce challenges without increasing taxpayer burdens or diverting essential resources.

“With the Alemian Retention System, public safety agencies can achieve full staffing levels and stop preventable turnover at zero net cost,” said David Alemian. “This solution is not theoretical—it is real, actionable, and designed for any size department in any city, anywhere in America,” David Alemian emphasized.

David Alemian has spent nearly three decades developing solutions that solve employee turnover and workforce retention challenges in both the public and private sectors. He has authored over 200 articles, produced 350 educational videos, and published the influential book “Talent Retention: How to Attract and Retain Highly Skilled Professionals.” His work has earned him recognition as America’s foremost expert on retention strategy, and the Alemian Retention System represents the apex of his contribution to solving the national first responder crisis.

Agencies, associations, and public safety officials seeking more information about the Alemian Retention System or wishing to schedule a confidential strategy session with David Alemian are encouraged to visit the contact information below. The opportunity to stop turnover, stabilize staffing, and strengthen community safety is now within reach.

Facebook

Instagram

Linkedin

X Twitter

Media Contact
Company Name: David Alemian’s Talent Retention System
Contact Person: David Alemian
Email: Send Email
Phone: 760-707-4797
City: Oceanside
State: California
Country: United States
Website: https://davidalemian.com/

Zenzap’s Streamlined Work Chat Platform for Modern Team Force

The chat app focuses on simplifying communication for industries like healthcare, construction,hospitality, restaurants and logistics, addressing the needs of modern workers.

Zenzap interduces its work chat platform built for businesses working on desktop, web or mobile, including healthcare, construction, hospitality, restaurants, professional services, logistics and more. The platform is designed to address communication challenges common among workers who often find traditional enterprise tools too complicated or unsuitable for their daily workflows.

Many teams still depend on personal messaging apps or informal communication methods like WhatsApp or iMessage . This reliance on non-work tools often leads to missed updates, scattered tasks, and security risks tied to using personal devices for work-related messaging. Zenzap aims to close this gap by offering a secure, structured chat app that keeps the simplicity of consumer messaging apps while adding features tailored for workplace coordination.

Guy Weiss, CEO of Zenzap said “We saw that many organizations defaulted to apps like WhatsApp or iMessage simply because they were easy to use, even though those tools aren’t designed for workplace security or structured collaboration. Zenzap bridges that gap by providing an app that’s as intuitive as personal messaging but purpose-built for work.”

Zenzap integrates messaging, task management, and file sharing into a single application, with a user interface designed to be accessible without training. Features such as real-time chat organized by team or project, built-in task assignments, file storage, and controlled onboarding and offboarding enable managers and staff to coordinate effectively without the complexity of traditional office software.

Industries with a high volume of workers, such as hospitals or logistics companies, often face difficulties maintaining consistent communication across teams working at different times or locations. Zenzap offers a unified, secure platform that replaces informal solutions like group texts and personal messaging threads, helping businesses safeguard data while maintaining professional boundaries.

Zenzap’s commitment to simplifying workplace communication for industries where usability and efficiency are key. The company addresses a longstanding gap in collaboration tools that has persisted as organizations increasingly rely on digital communication.

About Zenzap

Zenzap is the structured team chat app built for real work. Combining messaging, task management, file sharing, and admin tools in one secure, intuitive app, Zenzap helps modern teams communicate clearly and work better without the complexity. For more information, visit www.zenzap.co.

Media Contact
Company Name: Zenzap
Contact Person: Shelly
Email: Send Email
Country: United States
Website: https://www.zenzap.co

Revolutionary Home Improvement Platform Bidly.io Launches to Eliminate Wasted Time and Streamline Contractor-Client Connections

New platform addresses the $400+ billion home improvement industry’s biggest pain points with AI-powered project scoping and transparent bidding process

Bidly.io, an innovative digital platform designed to revolutionize the home improvement and construction bidding process, today announced its official launch. The comprehensive platform connects homeowners and property managers with qualified contractors through an efficient, transparent bidding system that eliminates the traditional time-wasting processes that plague both sides of the industry.

Solving a $400 Billion Industry’s Biggest Problem

The home improvement industry, valued at over $400 billion annually, has long suffered from inefficient communication and project matching. Traditional methods force contractors to spend hours driving to sites, preparing estimates, and chasing leads that often go nowhere, while homeowners struggle with unreliable contractors, ghost encounters, and lack of transparency in pricing.

“I created Bidly.io after experiencing firsthand the frustration of posting projects on social media and spending hours calling contractors, only to be left on voicemail,” said Paul Lorica, CEO and founder of Bidly.io. “Both contractors and homeowners were wasting 5+ hours per project just trying to connect. We knew there had to be a better way.”

Key Platform Features

For Contractors:

  • Submit detailed bids with pricing, timelines, and portfolio work
  • AI-powered project matching based on skills and location
  • Eliminate unnecessary site visits for simple estimates
  • Track bid success rates and market insights
  • Automated client communication and follow-up

For Homeowners:

  • Create detailed project listings with AI-powered scoping assistance
  • Compare multiple bids side-by-side with contractor profiles
  • Automatic contractor notifications when bids are accepted
  • Review system and contractor verification
  • Real-time project status tracking

Technology Integration:

  • AI-powered project scoping and cost estimation
  • Azure Blob storage for secure file management
  • Mapbox integration for location-based matching
  • Clerk authentication for user security
  • Real-time notifications and updates

Market Validation and Early Success

Since its beta launch, Bidly.io has demonstrated strong market validation:

  • Average time savings of 5+ hours per project for both contractors and homeowners
  • 85% reduction in unnecessary site visits for estimate-only projects
  • Growing user base across the DFW market
  • Positive feedback from early adopters praising the platform’s efficiency

“The traditional process was broken,” explains Paul Lorica. “Contractors were driving across town during rush hour, spending 10 minutes measuring, then going home tired to spend an hour on a takeoff, only to have clients ghost them. Meanwhile, homeowners were scheduling multiple site visits, taking time off work, and still only getting two bids back – one overpriced, one from a scammer.”

Competitive Advantage

Unlike existing platforms that focus primarily on lead generation, Bidly.io emphasizes:

  • Zero fees for basic platform usage (compared to expensive alternatives like Thumbtack)
  • Quality over quantity in contractor-client matching
  • Transparency in the bidding process with detailed bid comparisons
  • Time efficiency by eliminating unnecessary in-person meetings for simple estimates
  • Trust building through verified contractor profiles and review systems

Future Development and Investment

Bidly.io is currently in active development with several key features in the pipeline:

  • Enhanced bid management interfaces
  • Comprehensive contractor profile systems
  • In-app messaging and communication tools
  • Mobile app development
  • Payment integration via Stripe
  • Advanced search and filtering capabilities

The company is actively seeking strategic partnerships and investment opportunities to accelerate platform development and market expansion.

Industry Expert Commentary

“The home improvement industry has been ripe for digital disruption,” said Carlos Arrazo, Project Manager at Arrazo Roofing Inc. “Platforms like Bidly.io that focus on solving real pain points rather than just generating leads represent the future of how contractors and homeowners will connect.”

About Bidly.io

Founded in 2025, Bidly.io is a technology startup dedicated to streamlining the home improvement and construction project bidding process. The platform leverages modern technology including AI-powered project scoping, real-time communication tools, and comprehensive user verification systems to create a trustworthy, efficient marketplace for contractors and homeowners.

The platform currently serves the DFW Market and plans to expand nationwide throughout 2026. Bidly.io is committed to maintaining a free, open marketplace that prioritizes user experience and genuine value creation over profit extraction.

For more information about Bidly.io, visit www.bidly.io or follow the company on social media @BidlyIO.

Additional Resources

  • High-resolution images and logos: www.bidly.io
  • Platform demo video: www.bidly.io
  • Founder interview availability upon request
  • Platform screenshots and user testimonials available

Note to Editors: Bidly.io executives and beta users are available for interviews. Additional background information, statistics, and visual assets are available upon request.

This press release contains forward-looking statements about Bidly.io’s business plans and market opportunity. Actual results may vary.

Media Contact
Company Name: Bidly.io
Contact Person: Amy Lorica, Public Relations
Email: Send Email
Phone: 1 (682) 235-7183
City: Dallas
State: Texas
Country: United States
Website: www.bidly.io

Trio Mobil Showcases AI-Powered Safety Technologies at Safety 2025

Trio Mobil participated in Safety 2025, one of the Occupational Safety and Health (OSH) sector’s most influential events, held from July 22–24 at the Expo Center in Orlando. The three-day event brought together professionals from manufacturing, construction, logistics, and engineering with a shared focus on advancing safety practices and exploring the future of workplace risk management.

At Stand 2070, Trio Mobil presented its AI and IoT-based safety solutions, including TRIO SAFE AI, TRUE AI, and Trio SAFE. These systems are designed to support real-time monitoring, proactive risk detection, and automation of safety-critical functions within industrial facilities. The company’s presence at the event reflected its commitment to reshaping how organizations approach workplace safety through scalable, data-informed technologies.

Demonstrating Proactive Safety Technologies

Industrial safety is evolving and Trio Mobil is at the forefront of this transformation. At the ASSP Safety 25 Event, Trio Mobil showcased innovative technologies designed to move businesses from reactive measures to a proactive, data-driven safety culture.

Today’s high-risk environments demand more. They require intelligent systems that predict and prevent incidents before they happen. That’s exactly what Trio Mobil delivers.

What Trio Mobil ShowcasedTrio SAFE AI

Safety starts on the ground. Trio SAFE AI provides layered protection by combining AI-powered vision with UWB proximity detection technology. It offers both tag-based and tagless detection to eliminate blind spots and prevent forklift-pedestrian collisions in real time.

TRUE AI

When every second counts, visibility is everything. TRUE AI brings advanced computer vision for instant risk detection, operating without Wi-Fi or cellular dependency. It makes safety intelligent and reliable in any environment.

Vision Insights

From observation to prevention. Vision Insights turns raw safety data into predictive insights, helping organizations identify patterns, anticipate risks, and act before incidents occur.

The integration of these systems was a focal point in discussions with visitors looking to reduce incident rates and move toward preventive safety models. Participants expressed growing interest in solutions that not only detect risk in real time but also deliver the data needed to support long-term safety improvements.

Nevzat Atakli: “We’re moving beyond reactive measures.”

Nevzat Atakli, the CEO and co-founder of Trio Mobil, spoke on how artificial intelligence is transforming workplace safety: “Artificial intelligence is changing the way we think about workplace safety. We’re moving beyond reactive measures. Artificial intelligence empowers organizations to anticipate risks before they happen, making zero-incident operations an achievable reality.”

Executive Presence and Thought Leadership

Trio Mobil was represented at Safety 2025 by senior leadership, including CEO Nevzat Atakli, EVP Frederick Brown, Managing Director Chad Yildiz, and Director of National Accounts Nathan Sargent. The team engaged in dialogue with OSH professionals, consultants, and enterprise safety managers throughout the event and discussed common challenges in managing safety across increasingly automated and fast-paced environments.

Heather MacDougall: “This is where the industry is heading.”

Heather MacDougall, Advisory Board Member at Trio Mobil, emphasized the event’s relevance to the broader safety landscape: “Today’s safety conversations reinforce a critical truth: the future of workplace safety is proactive, data-driven, and technology-enabled. AI-powered safety systems are no longer optional; they are essential. Through advanced detection and predictive analytics, Trio Mobil is equipping organizations to prevent risks before they happen, setting a new benchmark for what workplace safety can achieve.”

Networking for Future Collaboration

Beyond the exhibition floor, Trio Mobil hosted an evening cocktail reception at The Hampton Social Orlando, bringing together professionals from across the OSH ecosystem, including industry leaders, plant managers, and safety consultants. The reception provided an engaging environment for meaningful discussions on shared safety objectives, evolving regulatory priorities, and the critical role of connected systems in advancing both safety and operational efficiency.

About Trio Mobil

Trio Mobil is a US-based company offering the industry’s only combined AI and IoT safety and efficiency solutions for manufacturing and warehousing businesses. With over 1,000,000 connected devices in 65 countries and 2,000+ customers, Trio Mobil has been instrumental in enhancing the operations of well-known brands such as Coca-Cola, Unilever, PepsiCo, Saint Gobain, Ford, and many more.

The company takes pride in its track record of saving lives and preventing injuries through innovative industrial and forklift safety systems. As the industrial safety and efficiency market grows, Trio Mobil remains committed to addressing unresolved safety issues and driving exponential growth.

For more information on Trio Mobil’s solutions, visit www.triomobil.com.

Media Contact
Company Name: Trio Mobil
Contact Person: Ebru Korkmazer
Email: Send Email
Country: United States
Website: https://www.triomobil.com/en

Award-Winning Educator and Leader Charles Tyler Announces Official Release of ‘Low-Key and Hater-Free: A Powerful New Guide to Living with Purpose and Peace’

Award-winning educator and leadership coach Charles Tyler proudly announces the official release of his latest book, ‘Low-Key and Hater-Free: A Statement. A Mission. A Lifestyle’. This new book is now available through through www.charlesetyler.com and Amazon and offers a timely, empowering guide that challenges the pressure of a performance-driven culture and invites readers to reclaim control of their mindset, emotions, and peace.

Tyler is helping others forge a successful future by shaping lasting leadership mindsets in those he reaches. In a recent article published by Conglomerate, Tyler shares how he cultivates authentic leadership and purpose in “the age of distraction”. He shares even more insight in his groundbreaking book, ‘Low-Key and Hater-Free: A Statement. A Mission. A Lifestyle.’

Blending personal insight with real-world reflection, Tyler breaks down what it truly means to live a low-key life – one free from drama, toxic comparison, and the demand to constantly perform. Each chapter equips readers with tools to build emotional resilience, set healthy boundaries, and live with quiet confidence instead of loud validation. The book dives into critical themes such as emotional awareness, setting boundaries, protecting mental health, and navigating today’s toxic digital culture. Whether you’re a young adult navigating identity, a leader burned out by pressure, or someone simply looking for peace in the chaos, Tyler’s practical advice and relatable stories will hit home. Each chapter includes exercises and examples designed to help readers apply the “low-key and hater-free” mindset to their own lives.

“Low-Key and Hater-Free isn’t just a catchy phrase – it’s a movement,” says Tyler. “This book speaks to those who are tired of keeping up appearances and are ready to start living with intention, clarity, and purpose.”

With relatable stories, self-reflection prompts, and bold encouragement, ‘Low-Key and Hater-Free’ is a must-read for anyone ready to protect their peace and live life on their own terms – authentically and unapologetically. Learn more now by visiting www.charlesetyler.com.

About the Author

Charles Tyler is a certified life coach, youth mentor, and one of the most credentialed professionals in leadership and personal development. His mission is to inspire people to lead intentional, grounded lives rooted in peace, clarity, and purpose.

Media Contact
Contact Person: Charles Tyler
Email: Send Email
City: Birmingham
State: Alabama
Country: United States
Website: www.charlesetyler.com

Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion

The Key Metastatic Prostate Cancer Companies in the market include – Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others.

 

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Metastatic Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Prostate Cancer Market Forecast

 

Some of the key facts of the Metastatic Prostate Cancer Market Report:

  • The Metastatic Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In June 2025, Johnson & Johnson, a US-based pharmaceutical firm, has released Phase I trial data for its bispecific antibody, pasritamig, targeting metastatic castration-resistant prostate cancer (mCRPC). The first-in-human study involved 174 participants aged 36 to 89, who had previously received an average of four treatments. Findings from the trial showed that pasritamig was well-tolerated and exhibited promising anti-tumor activity in patients with mCRPC.

  • In May 2025, Janux Therapeutics initiated Phase Ib expansion studies of JANX007 as part of the ongoing first-in-human ENGAGER-PSMA-01 clinical trial, targeting patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This open-label, multicenter Phase I trial is designed to evaluate the tolerability, safety, pharmacodynamics, pharmacokinetics, and preliminary efficacy of JANX007, either as a monotherapy or in combination therapy, in adult patients with advanced mCRPC. The initial Phase Ib segment will enroll taxane-naïve mCRPC patients, focusing on those in first-line (1L) and second-line (2L) treatment settings. Two dosing regimens—0.3/2/6mg and 0.3/2/9mg—of JANX007 monotherapy are being assessed for their safety and effectiveness.

  • In May 2025, Astellas and Pfizer have shared five-year follow-up results from the open-label extension of the Phase III ARCHES trial. The findings revealed that Xtandi (enzalutamide), when used in combination with androgen deprivation therapy (ADT), led to a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC). Patients receiving this combination therapy demonstrated improved survival outcomes compared to those treated with placebo plus ADT.

  • In March 2025, The FDA has granted approval to Novartis’ radioligand therapy, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), for use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already undergone treatment with an androgen receptor pathway inhibitor (ARPI) and are suitable candidates for postponing chemotherapy.

  • In March 2025, MacroGenics is discontinuing the development of one of its antibody-drug conjugates (ADC) following disappointing results in a Phase II prostate cancer study. The Rockville, Maryland-based biotech announced that trials of vobramitamab duocarmazine (vobra duo) will be halted, as the safety and efficacy data from the TAMARACK Phase II study (NCT05551117) did not justify further financial investment.

  • In March 2025, Janux Therapeutics initiated Phase Ib expansion studies of JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial targeting advanced metastatic castration-resistant prostate cancer (mCRPC). This open-label, multicenter Phase I trial aims to evaluate the tolerability, pharmacodynamics, safety, preliminary efficacy, and pharmacokinetics of JANX007 as a standalone treatment or in combination therapy for adults with advanced mCRPC.

  • In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx in combination with atezolizumab for mCRPC demonstrated a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.

  • In August 2024, Nuvation Bio announced that the US Food and Drug Administration has approved its investigational new drug application to study NUV-1511, the first clinical candidate developed from the company’s innovative drug-drug conjugate (DDC) platform.

  • In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

  • In June 2024, Kangpu Biopharmaceuticals secured FDA approval to conduct a Phase II/III trial of KPG-121 in combination with Abiraterone for metastatic castration-resistant prostate cancer (mCRPC).

  • In June 2024, BioNTech SE and Duality Biologics announced that the US Food and Drug Administration has granted Fast Track designation to BNT324/DB-1311 for the treatment of patients with advanced, unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have progressed following standard systemic treatments.

  • In May 2024, Fusion Pharmaceuticals launched the Phase II AlphaBreak trial of FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC).

  • According to DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets (7MM) was approximately 8,241,400 cases in 2023. This number is expected to rise over the study period.

  • In 2023, the United States had the highest number of diagnosed prostate cancer cases, with approximately 1,506,200 reported cases.

  • In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in locally advanced stages (Stage I–III), with over 903,700 cases in 2023, followed by biochemical recurrence/progressive and metastatic cases, respectively.

  • Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others

  • Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others

  • The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics.

 

Metastatic Prostate Cancer Overview

Metastatic prostate cancer is an advanced stage of prostate cancer in which the cancer cells have spread beyond the prostate gland to other parts of the body, most commonly the bones, lymph nodes, liver, or lungs. This occurs when cancer cells break away from the original tumor and travel through the bloodstream or lymphatic system. Symptoms may include bone pain, fatigue, weight loss, and difficulty urinating. While it is not curable, treatments like hormone therapy, chemotherapy, targeted therapy, and radiation can help manage symptoms and slow disease progression.

 

Get a Free sample for the Metastatic Prostate Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

 

Metastatic Prostate Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Metastatic Prostate Cancer Epidemiology Segmentation:

The Metastatic Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Metastatic Prostate Cancer

  • Prevalent Cases of Metastatic Prostate Cancer by severity

  • Gender-specific Prevalence of Metastatic Prostate Cancer

  • Diagnosed Cases of Episodic and Chronic Metastatic Prostate Cancer

 

Download the report to understand which factors are driving Metastatic Prostate Cancer epidemiology trends @ Metastatic Prostate Cancer Epidemiology Forecast

 

Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Metastatic Prostate Cancer Therapies and Key Companies

  • 177Lu-PSMA-I&T: Curium US LLC

  • Darolutamide (Nubeqa, BAY1841788): Bayer

  • HB-302/HB-301: Hookipa Biotech GmbH

  • Enzalutamide: University Health Network

  • Opevesostat: Merck Sharp & Dohme

  • Pembrolizumab: Merck Sharp & Dohme

  • ARV-766 Part A&B: Arvinas Androgen Receptor

  • Darolutamide: UNICANCER

  • Apalutamide: Aragon Pharmaceuticals

  • REGN2810: Mark Stein

  • 177Lu-PSMA-617: Novartis

  • ODM-208: Orion Corporation, Orion Pharma

  • Apalutamide: Janssen Research & Development

  • AZD0754: AstraZeneca

  • Enzalutamide: MedSIR

  • Apalutamide: Aragon Pharmaceuticals

  • Niraparib: Janssen Research & Development

  • 177Lu-DOTA-rosopatamb: Telix Pharmaceuticals

  • Darolutamide: Alliance Foundation Trials

  • Tazemetostat: Epizyme, Inc.

  • Cabozantinib: Exelixis

 

Discover more about therapies set to grab major Metastatic Prostate Cancer market share @ Metastatic Prostate Cancer Treatment Landscape

 

Metastatic Prostate Cancer Market Strengths

  • The emergence of PASMA-PET imaging have significantly improved the diagnostic landscape of advance prostate cancer.

  • Astella’s XTANDI, which has approval in maximum prostate cancer indications is the highest revenue generator among all approved therapies in prostate cancer. Though XTANDI’s revenue is driven by prescribing volume, an increasing share of the drug’s revenue is driven by price increases in recent years.

 

Metastatic Prostate Cancer Market Opportunities

  • The developmental pipeline for mCSPC is dry compared to that of mCRPC. Thus, the market for mCSPC holds considerable scope for upcoming therapies owing to the availability of only a handful of approved drugs for its patient pool.

  • Although triplet therapy techniques have not yet been fully investigated, analysis shows that patients with de novo metastatic disease and a high-volume disease burden benefited most from this approach.

 

Scope of the Metastatic Prostate Cancer Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others

  • Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others

  • Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies

  • Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement

 

To know more about Metastatic Prostate Cancer companies working in the treatment market, visit @ Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Metastatic Prostate Cancer Market Report Introduction

2. Executive Summary for Metastatic Prostate Cancer

3. SWOT analysis of Metastatic Prostate Cancer

4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance

5. Metastatic Prostate Cancer Market Overview at a Glance

6. Metastatic Prostate Cancer Disease Background and Overview

7. Metastatic Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Prostate Cancer

9. Metastatic Prostate Cancer Current Treatment and Medical Practices

10. Metastatic Prostate Cancer Unmet Needs

11. Metastatic Prostate Cancer Emerging Therapies

12. Metastatic Prostate Cancer Market Outlook

13. Country-Wise Metastatic Prostate Cancer Market Analysis (2020–2034)

14. Metastatic Prostate Cancer Market Access and Reimbursement of Therapies

15. Metastatic Prostate Cancer Market Drivers

16. Metastatic Prostate Cancer Market Barriers

17. Metastatic Prostate Cancer Appendix

18. Metastatic Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion

The Healing Frequency: How INDIBA® 448kHz + 20kHz Is Revolutionizing Recovery For Athletes and Everyone Else

Imagine waking up with stiff joints that make simple tasks feel like a chore. Or picture an athlete who’s just tore a ligament days before a big competition. Whether you’re a weekend warrior, a professional footballer, or simply dealing with aging joints, one thing is universal: you want to recover fast, safely, and fully.

This is where INDIBA® 448 kHz + 20kHz steps in, not just as a therapy, but as a science-backed solution that’s transforming recovery around the world. Whether you’re managing chronic pain, healing post-surgery, or preparing for your next workout, INDIBA®’s technology is changing the way people move, heal, and live.

What Makes INDIBA® Different? It Goes Deeper—Literally.

INDIBA®’s Proionic® System is a patented technology that delivers radiofrequency energy at 448kHz + 20 kHz. It’s a non-invasive treatment that combines deep thermal effects with cellular-level stimulation, working from the inside out.

Unlike surface-level treatments, this frequency penetrates deep into muscles, joints, and even stem cells, stimulating natural cellular repair and regeneration without medication, needles, or downtime.

Science That Doesn’t Just Sound Good—It Works

Two major studies show how INDIBA® stands out:

1. Deep Therapeutic Heat for Lasting Healing

A study published in the International Journal of Hyperthermia found that INDIBA®’s treatment raised deep tissue temperature and sustained mild hyperthermia for up to 45 minutes (Kumaran & Watson, 2015). Why does this matter?

Because heat does more than soothe it:

  • Boosts blood flow to bring oxygen and nutrients
  • Relieves pain to enable early movement
  • Improves flexibility and range of motion

For someone recovering from age-related stiffness, this means walking sooner, stretching easier, and living better.

2. It Stimulates Cellular Regeneration

A second study uncovered something even more fascinating: INDIBA®’s frequency actually stimulates stem cell activity. Researchers found that 448kHz + 20kHz encourages stem cells to start rebuilding cartilage producing more collagen and healing tissues that typically don’t regenerate well (Hernández-Bule et al.).

This unlocks exciting new possibilities for managing osteoarthritis, joint degeneration, and sports injuries that once thought to require long-term care.

Why the World’s Top Athletes Use INDIBA® And You Should Too

When milliseconds and muscle recovery make the difference between gold and silver, elite athletes choose INDIBA®. Discover why champions trust us, explore the INDIBA Hall of Fame.

From sports champions to global football clubs, INDIBA® is a trusted partner of their recovery toolkit. But you don’t have to be a pro to feel the difference. Everyday users — parents, seniors, fitness lovers — turn to INDIBA® for:

  • Post-operative recovery
  • Sports injury management
  • Chronic pain relief
  • Preventive wellness

Because everybody deserves to move better, feel better, and live better.

Clinics Trust It. Patients Feel It. Science Proves It.

Physio centres, sports rehab clinics, and wellness facilities across the world are making INDIBA® part of their practice because:

  • It’s backed by over 40 years of science
  • It’s non-invasive, pain-free, and with zero downtime
  • It improves patient satisfaction with faster, more noticeable results

Whether it’s getting someone back on the tennis court, walking pain-free, or simply living with less discomfort, INDIBA® delivers more than just therapy. It delivers confidence, comfort, and quality of life.

Healing Powered by Frequency: INDIBA® 448kHz + 20kHz

At its core, INDIBA® is about restoring better movement, relieving pain, and accelerating recovery for everybody, at every stage. That’s why it’s trusted by clinicians, therapists, and elite athletes around the world. Whether it’s for you or your patients, INDIBA® helps get life moving again, back to what truly matters.

References:

  • Kumaran B, Watson T. International Journal of Hyperthermia, 2015. DOI: 10.3109/02656736.2015.1092172
  • Hernández-Bule ML et al. Journal of Stem Cell Research & Therapy. DOI: 10.4172/2157-7633.1000407

Media Contact
Company Name: Indiba Asia Pte Ltd
Contact Person: Lam
Email: Send Email
Country: Singapore
Website: www.indibasia.com

Glaucoma Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Q BioMed, InMed Pharma, ONL Therapeutics, Mitotech, TheratOcular Biotek

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Glaucoma pipeline constitutes 50+ key companies continuously working towards developing 50+ Glaucoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Glaucoma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glaucoma Market.

 

The Glaucoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Glaucoma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Glaucoma treatment therapies with a considerable amount of success over the years.

  • Glaucoma companies working in the treatment market are Q BioMed, InMed Pharmaceuticals, ONL Therapeutics, Mitotech, TheratOcular Biotek Co., Ltd., AbbVie, JeniVision, Qlaris Bio, VivaVivion Biotech, Inc., Nicox, Tarsier Pharma Ltd, Santen Pharmaceutical, and others, are developing therapies for the Glaucoma treatment

  • Emerging Glaucoma therapies in the different phases of clinical trials are- MAN-01, INM-088, ONL 1204, Visomitin, TO-O-1001, AGN-193408, JV-GL1, QLS-101, VVN539, NCX 470, TRS01, STN-1012600, and others are expected to have a significant impact on the Glaucoma market in the coming years.

  • In June 2025, Perfuse Therapeutics, Inc., a biopharmaceutical company focused on developing breakthrough treatments for ischemia-related eye diseases, has announced promising outcomes from two Phase 2 trials of its novel therapy, PER-001. The six-month, randomized, controlled studies evaluated PER-001—a first-in-class endothelin antagonist delivered via a slow-release, dissolvable intravitreal implant—administered every six months. The trials showed significant vision improvement in patients with glaucoma and diabetic retinopathy compared to controls. By targeting the root cause of both conditions, PER-001 demonstrated the potential to halt or reverse vision loss by enhancing retinal blood flow and preserving retinal cells. Phase 2b/3 trials are set to begin in late 2025.

 

Glaucoma Overview

Glaucoma is a group of eye conditions that damage the optic nerve, which is crucial for good vision. It’s often associated with high pressure inside the eye, known as intraocular pressure. Glaucoma can lead to gradual vision loss and, if untreated, eventual blindness.

 

Get a Free Sample PDF Report to know more about Glaucoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/glaucoma-pipeline-insight

 

Emerging Glaucoma Drugs Under Different Phases of Clinical Development Include:

  • MAN-01: Q BioMed

  • INM-088: InMed Pharmaceuticals

  • ONL 1204: ONL Therapeutics

  • Visomitin: Mitotech

  • TO-O-1001: TheratOcular Biotek Co., Ltd.

  • AGN-193408: AbbVie

  • JV-GL1: JeniVision

  • QLS-101: Qlaris Bio

  • VVN539: VivaVivion Biotech, Inc.

  • NCX 470: Nicox

  • TRS01: Tarsier Pharma Ltd

  • STN-1012600: Santen Pharmaceutical

 

Glaucoma Route of Administration

Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

 

Glaucoma Molecule Type

Glaucoma Products have been categorized under various Molecule types, such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

 

Glaucoma Pipeline Therapeutics Assessment

  • Glaucoma Assessment by Product Type

  • Glaucoma By Stage and Product Type

  • Glaucoma Assessment by Route of Administration

  • Glaucoma By Stage and Route of Administration

  • Glaucoma Assessment by Molecule Type

  • Glaucoma by Stage and Molecule Type

 

DelveInsight’s Glaucoma Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Glaucoma product details are provided in the report. Download the Glaucoma pipeline report to learn more about the emerging Glaucoma therapies

 

Some of the key companies in the Glaucoma Therapeutics Market include:

Key companies developing therapies for Glaucoma are – Aerie Pharmaceuticals Inc., Akorn, Incorporated, Abbvie Inc. (Allergan Plc), Bausch Health (Bausch & Lomb Incorporated), Inotek Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc, Santen Pharmaceutical Co., Ltd., and others.

 

Glaucoma Pipeline Analysis:

The Glaucoma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Glaucoma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glaucoma Treatment.

  • Glaucoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Glaucoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glaucoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Glaucoma drugs and therapies

 

Glaucoma Pipeline Market Drivers

  • Growing Prevalence of glaucoma, development of novel therapies, growing awareness due to government initiatives and pharmaceutical companies are some of the important factors that are fueling the Glaucoma Market.

 

Glaucoma Pipeline Market Barriers

  • However, high medical cost, side-effects associated with the drugs and other factors are creating obstacles in the Glaucoma Market growth.

 

Scope of Glaucoma Pipeline Drug Insight

  • Coverage: Global

  • Key Glaucoma Companies: Q BioMed, InMed Pharmaceuticals, ONL Therapeutics, Mitotech, TheratOcular Biotek Co., Ltd., AbbVie, JeniVision, Qlaris Bio, VivaVivion Biotech, Inc., Nicox, Tarsier Pharma Ltd, Santen Pharmaceutical, and others

  • Key Glaucoma Therapies: MAN-01, INM-088, ONL 1204, Visomitin, TO-O-1001, AGN-193408, JV-GL1, QLS-101, VVN539, NCX 470, TRS01, STN-1012600, and others

  • Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies

  • Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers

 

Request for Sample PDF Report for Glaucoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Glaucoma Report Introduction

2. Glaucoma Executive Summary

3. Glaucoma Overview

4. Glaucoma- Analytical Perspective In-depth Commercial Assessment

5. Glaucoma Pipeline Therapeutics

6. Glaucoma Late Stage Products (Phase II/III)

7. Glaucoma Mid Stage Products (Phase II)

8. Glaucoma Early Stage Products (Phase I)

9. Glaucoma Preclinical Stage Products

10. Glaucoma Therapeutics Assessment

11. Glaucoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Glaucoma Key Companies

14. Glaucoma Key Products

15. Glaucoma Unmet Needs

16 . Glaucoma Market Drivers and Barriers

17. Glaucoma Future Perspectives and Conclusion

18. Glaucoma Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glaucoma Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Q BioMed, InMed Pharma, ONL Therapeutics, Mitotech, TheratOcular Biotek

Hearing Loss Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hearing Loss pipeline constitutes 32+ key companies continuously working towards developing 35+ Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Hearing Loss Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hearing Loss Market.

 

The Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Hearing Loss Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Hearing Loss treatment therapies with a considerable amount of success over the years.

  • Hearing Loss companies working in the treatment market are Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others, are developing therapies for the Hearing Loss treatment

  • Emerging Hearing Loss therapies in the different phases of clinical trials are- ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others are expected to have a significant impact on the Hearing Loss market in the coming years.

  • In July 2025, Rinri Therapeutics, a University of Sheffield spinout focused on developing regenerative cell therapies for sensorineural hearing loss (SNHL), received regulatory approval to launch its first-in-human clinical trial. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has cleared Rincell-1, a pioneering otic neural progenitor cell therapy, for a Phase I/IIa trial. Initial clinical proof-of-concept data is anticipated within 12 months of the trial’s commencement.

  • In February 2025, Currently, no drug has been globally approved for the treatment of sudden hearing loss. However, the innovative drug candidate AC102 has shown encouraging results in preclinical and Phase I clinical studies. Berlin-based start-up AudioCure Pharma, backed by investors, is spearheading its research and development. InfectoPharm, a well-established mid-sized company specializing in ENT, has now joined as a key strategic partner. Based in Heppenheim, InfectoPharm is leading the latest funding round and reinforcing the existing investor group, which includes lead investor MED-EL and early-stage backer High-Tech Gründerfonds (HTGF). The collaboration aims to advance the clinical development of AC102.

  • In February 2025, Sound Pharmaceuticals is excited to share that it will deliver four presentations at the upcoming Association for Research in Otolaryngology MidWinter Meeting. One of the key presentations, titled “The Development of SPI-1005 for the Treatment of Hearing Loss and Tinnitus,” will be featured at the Pharmaceutical Interventions for Hearing Loss (PIHL) Satellite Symposium. Organized by the Defense Health Agency (DHA) Hearing Center of Excellence (HCE) committee, this symposium will offer an in-depth review of investigational treatments aimed at preventing hearing loss and promoting hearing restoration.

  • In January 2025, US-based dermatology biopharma Eirion Therapeutics reported positive findings from its first-in-human, double-blind, placebo-controlled study of its topical treatment for age-related hair loss, demonstrating a six-fold increase in hair count over placebo. ET-02, the company’s most advanced therapy for androgenic alopecia, was evaluated in a trial involving 24 male patients across three US sites, successfully meeting its primary safety and tolerability endpoints. Additionally, Eirion Therapeutics is advancing a preclinical oral version of ET-02, further expanding its pipeline for hair loss treatments.

  • In August 2024, Pelage Pharmaceuticals, a clinical-stage company specializing in regenerative medicine for hair loss, commenced its Phase 2a clinical trial for PP405, a novel topical small molecule aimed at treating androgenetic alopecia (pattern baldness). The first patients have been dosed, and the study will evaluate the drug’s safety and effectiveness. The trial plans to enroll 60 men and women, with PP405 designed to activate dormant hair follicle stem cells, promoting hair growth

 

Hearing Loss Overview

Hearing Loss (SNHL) occurs due to damage to inner ear structures or the auditory nerve. It accounts for over 90 percent of hearing impairment in adults. Typical causes of SNHL include prolonged exposure to loud noises, genetic predisposition, or the natural aging process.

 

Get a Free Sample PDF Report to know more about Hearing Loss Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hearing-loss-pipeline-insight

 

Emerging Hearing Loss Drugs Under Different Phases of Clinical Development Include:

ACOU085: Acousia Therapeutics

  • Cochlear Hair Cell Regeneration: Decibel Therapeutics

  • HY01: Suzhou Pharmaceutical Technology Co.,Ltd

  • AC102: AudioCure Pharma GmbH

  • SENS-401: Sensorion

 

Hearing Loss Route of Administration

Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

 

Hearing Loss Molecule Type

Hearing Loss Products have been categorized under various Molecule types, such as

  • Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

 

Hearing Loss Pipeline Therapeutics Assessment

  • Hearing Loss Assessment by Product Type

  • Hearing Loss By Stage and Product Type

  • Hearing Loss Assessment by Route of Administration

  • Hearing Loss By Stage and Route of Administration

  • Hearing Loss Assessment by Molecule Type

  • Hearing Loss by Stage and Molecule Type

 

DelveInsight’s Hearing Loss Report covers around 35+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Hearing Loss product details are provided in the report. Download the Hearing Loss pipeline report to learn more about the emerging Hearing Loss therapies

 

Some of the key companies in the Hearing Loss Therapeutics Market include:

Key companies developing therapies for Hearing Loss are – Sensorion, Fennec Pharmaceuticals, Sound Pharmaceuticals, Decibel Therapeutics, Akouos, and others.

 

Hearing Loss Pipeline Analysis:

The Hearing Loss pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hearing Loss with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hearing Loss Treatment.

  • Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hearing Loss market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Hearing Loss drugs and therapies

 

Hearing Loss Pipeline Market Drivers

  • Rise in the Incidence of Hearing Loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Hearing Loss Market.

 

Hearing Loss Pipeline Market Barriers

  • However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Hearing Loss Market growth.

 

Scope of Hearing Loss Pipeline Drug Insight

  • Coverage: Global

  • Key Hearing Loss Companies: Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others

  • Key Hearing Loss Therapies: ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others

  • Hearing Loss Therapeutic Assessment: Hearing Loss current marketed and Hearing Loss emerging therapies

  • Hearing Loss Market Dynamics: Hearing Loss market drivers and Hearing Loss market barriers

 

Request for Sample PDF Report for Hearing Loss Pipeline Assessment and clinical trials

 

Table of Contents

1. Hearing Loss Report Introduction

2. Hearing Loss Executive Summary

3. Hearing Loss Overview

4. Hearing Loss- Analytical Perspective In-depth Commercial Assessment

5. Hearing Loss Pipeline Therapeutics

6. Hearing Loss Late Stage Products (Phase II/III)

7. Hearing Loss Mid Stage Products (Phase II)

8. Hearing Loss Early Stage Products (Phase I)

9. Hearing Loss Preclinical Stage Products

10. Hearing Loss Therapeutics Assessment

11. Hearing Loss Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hearing Loss Key Companies

14. Hearing Loss Key Products

15. Hearing Loss Unmet Needs

16 . Hearing Loss Market Drivers and Barriers

17. Hearing Loss Future Perspectives and Conclusion

18. Hearing Loss Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hearing Loss Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos